Jazz Pharmaceuticals plc — Director's Dealing 2025

Dec 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-12-05

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-05	Ordinary Shares	S	160	$171.11	Disposed	7012	Direct
2025-12-05	Ordinary Shares	M	4500	$140.67	Acquired	11512	Direct
2025-12-05	Ordinary Shares	S	4500	$171.2012	Disposed	7012	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-05	Non-Qualified Stock Option (right to buy)	$140.67	M	4500	Disposed	2028-02-29	Ordinary Shares (4500)	Direct

Footnotes

F1: The Reporting Person acquired 160 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $171.2001 to $171.2601. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option fully vested as of March 1, 2022.